Theratechnologies shareholders approve Future Pak acquisition plan

Theratechnologies Inc. (NASDAQ: THTX) announced that shareholders approved a plan of arrangement for the company's acquisition by CB Biotechnology, LLC, an affiliate of Future Pak, LLC.

At a special shareholder meeting held September 12, the arrangement resolution received approval from 97.44% of votes cast by shareholders present or represented by proxy. When excluding votes required to be excluded under Multilateral Instrument 61-101, the approval rate was 97.43%.

The Montreal-based biopharmaceutical company said the proposed arrangement remains subject to customary closing conditions, including a final order from the Superior Court of Québec. A hearing for this approval is expected to take place on September 16, 2025.

Future Pak, founded in 1977 and headquartered in Wixom, Michigan, operates as a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. The company serves retail, specialty and institutional markets.

Theratechnologies describes itself as a commercial-stage biopharmaceutical company focused on commercializing therapies. The company's shares trade on both the Toronto Stock Exchange and NASDAQ.

The information was disclosed in a company press release statement.

You May Also Be Interested In

• Dutch Bros to acquire up to 65 Salad and Go sites for conversion
• AXIS Capital to acquire renewal rights to DUAL North America excess liability book
• LTC Properties closes $95M acquisition of two Minnesota senior communities